Latest Graft-versus-host disease Stories
In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients.
US drug regulators for the first time have approved a therapy using cells of human blood from the placenta and the umbilical cord to treat cancer or blood-forming disorders.
Older patients with advanced hematologic malignancies, such as leukemia and lymphoma, who received a conditioning regimen that included minimal-intensity radiation therapy prior to allogeneic (genetically different) hematopoietic cell transplantation (HCT; receipt of bone marrow or stem cells transplant) had survival and progression-free survival outcomes suggesting that this treatment approach may be a viable option for older patients with these malignancies.
Age alone no longer should be considered a defining factor when determining whether an older patient with blood cancer is a candidate for stem cell transplantation.
Graft-versus-host disease (GVHD) is a serious risk in many kinds of cell transplants, including for stem cell transplants carried out when stem cells are partially depleted of conventional T cells, which play an important role in the immune system.
NEW YORK, Aug. 17, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd.
- The abrogation of a law by a higher authority; annulment.